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A b s t r a c t
Left ventricular hypertrophy (LVH) is traditionally considered a physiological compensatory response to LV pressure overload, such 
as hypertension and aortic stenosis (AS), in an effort to maintain LV systolic function in the face of an increased afterload. According to 
the Laplace law, LV wall thickening lowers LV wall stress, which in turn would be helpful to preserve LV systolic performance. However, 
numerous studies have challenged the notion of LVH as a putative beneficial adaptive mechanism. In fact, the magnitude of LVH is 
associated with higher cardiovascular morbidity and mortality, especially when LVH is disproportionate to LV afterload. We have briefly 
reviewed: first, the importance of non-valvular factors, beyond AS severity, for total LV afterload and symptomatic status in AS patients; 
second, associations of excessive LVH with LV dysfunction and adverse outcome in AS; third, prognostic relevance of the presence or 
absence of pre-operative LVH in patients referred for aortic valve surgery; fourth, time course, determinants and prognostic implica-
tions of LVH regression and LV function recovery after surgical valve replacement and transcatheter aortic valve implantation (TAVI) 
with a focus on TAVI-specific effects; fifth, the potential of medical therapy to modulate LVH before and after surgical or interventional 
treatment for severe AS, a condition perceived as a relative contraindication to renin-angiotensin system blockade.
Key words: aortic valve stenosis, cardiac valve surgery, left ventricular function, left ventricular hypertrophy, prognosis, trans-
catheter aortic valve implantation.
Introduction
Every medical student is taught that the compensa-
tory response to increased left ventricular (LV) afterload 
by the heart is left ventricular hypertrophy (LVH). The 
heart muscle increases the size of myocytes, making the 
heart stronger and better able to cope with the increased 
pressure it has to pump against. 
A  common cause of increased LV afterload on the 
heart, especially when we age, is the age-dependent in-
crease in blood pressure, frequently associated with re-
duced compliance of large systemic arteries, a basis of 
isolated systolic hypertension [1]. Degenerative changes 
of aortic valve leaflets sometimes progress into aortic 
valve stenosis (AS), the most prevalent valve disease 
in the elderly, which further contributes to LV pressure 
overload. Then, both hypertension and AS jointly impede 
blood flow from the left ventricle into the aorta and en-
hance LVH development. 
According to traditional teaching, LVH is perceived as 
a compensatory – and probably also beneficial – mech-
anism aimed to lower LV wall stress by the Laplace law, 
thereby facilitating LV systolic performance despite 
chronic pressure overload. However, the notion of LVH as 
an advantageous LV adaptation has been challenged by 
recent evidence, suggesting that perhaps we have been 
thinking about LVH incorrectly. In essential hypertension, 
it has been demonstrated that the degree of LVH is as-
sociated with adverse outcomes [2], especially when the 
magnitude of LVH is disproportionate to LV afterload. Ex-
cessive LVH is associated with LV diastolic [3] and subtle 
systolic dysfunction [3–5] as well as impaired coronary 
flow reserve [6] in hypertensive subjects, which acceler-
ates the development of heart failure and translates into 
worse long-term prognosis [7, 8]. 
We aimed to review: first, the importance of non-val-
vular factors, beyond AS severity, for total LV afterload 
and symptomatic status in AS patients; second, associ-
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ations of excessive LVH with LV dysfunction and adverse 
outcome in AS; third, prognostic relevance of the pres-
ence or absence of pre-operative LVH in patients referred 
for aortic valve surgery; fourth, time course, determi-
nants and prognostic implications of LVH regression and 
LV function recovery after surgical valve replacement and 
transcatheter aortic valve implantation (TAVI) with a fo-
cus on TAVI-specific effects; fifth, the potential of medi-
cal therapy to modulate LVH before and after surgical or 
interventional treatment for severe AS, a condition per-
ceived as a relative contraindication to renin-angiotensin 
system blockade.
Vascular stiffening – a contributor to LV  
afterload and dysfunction in AS
Depressed compliance of large systemic arteries, i.e. 
reduced systemic arterial compliance (SAC), is observed 
during normal human aging. Beyond age, diabetes, renal 
disease, hypertension and atherosclerosis all contribute 
to decreased arterial distensibility and compliance [1, 9]. 
These abnormalities are linked to progressive fragmen-
tation of elastic fibers and increased collagen content 
in the thickened vascular wall, as well as excessive 
cross-linking of elastin and collagen, which transfers the 
mechanical load into much stiffer collagen fibers. Accord-
ingly, the vessel becomes less distensible and as a result 
the pulse wave velocity (PWV) increases. Pulse wave ve-
locity is commonly understood as the speed at which the 
pressure wave from the heart moves through the vascu-
lar system, and its measurement has become the gold 
standard for measuring SAC. When the PWV is greater, as 
it occurs in non-compliant elastic arteries, there is a phe-
nomenon of increased late systolic pressure due to an 
earlier return of the pulse wave reflection back to the 
heart. This causes a  higher central systolic pressure in 
the elderly which ultimately leads to increases in the LV 
afterload [9]. 
The increased afterload from large vessel stiffening 
consequentially slows LV relaxation, which corresponds 
to an early phase of diastolic dysfunction. A concomitant 
reduction in central diastolic pressure may also compro-
mise coronary perfusion and potentiate subendocardial 
ischemia, which can further impair myocardial relaxation 
and promote myocardial fibrosis, aggravating diastolic 
dysfunction via increased passive myocardial stiffness 
[9]. This destructive cycle initiates the development of 
heart failure symptoms in AS, despite a normal ejection 
fraction (EF), and provides a link between depressed SAC 
and heart failure with preserved EF. 
Briand et al. [10] emphasized that reduced SAC was 
a critical component in the pathogenesis of LV dysfunc-
tion, acting via increased LV afterload. They demonstrat-
ed that in patients with AS accompanied by severely 
depressed SAC and consequent systolic hypertension, 
valvulo-arterial impedance, an index of global LV after-
load, can be especially high, which predisposes them to 
the occurrence of both symptoms and LV systolic and 
diastolic dysfunction independently of AS severity [10]. 
They argued that assessing AS based solely on valvular 
hemodynamics can overlook contributing factors distal 
to the valve that are responsible for elevated afterload. 
In particular, developing LV systolic dysfunction may 
result in stroke volume lowering and systolic pressure 
pseudo-normalization, which can mask the contribution 
of excessive arterial stiffness to LV afterload. According-
ly, they recommended routine calculations of SAC from 
echocardiography – as stroke volume index divided by 
pulse pressure – to avoid this pitfall [10]. This further 
demonstrates that the degenerative process in largely 
elderly patients with AS is a systemic problem that is not 
confined to the aortic valve. 
Non-valvular factors – predictors  
of symptoms development in AS
As mentioned above, depressed SAC and elevated 
valvulo-arterial impedance are associated not only with 
LV systolic and diastolic dysfunction, but also symptom-
atic status in AS [10]. This notion has been widely sup-
ported by later evidence with regard to exercise capacity 
in AS subjects. In patients with asymptomatic moderate 
or severe AS and a preserved EF, increased arterial val-
vulo-arterial impedance was an independent predictor 
of reduced peak oxygen uptake, as shown by Dulgheru 
et al. [11]. Similarly, the vascular component of LV after-
load in AS appears to be associated with the presence of 
symptoms [12] or exercise intolerance [13]. In agreement 
with these observations, our group has recently shown 
that depressed SAC predicted the degree of exercise in-
tolerance independently of AS severity and EF, in a retro-
spective cross-sectional analysis of patients with mod-
erate-to-severe AS [14], which supports the relevance of 
non-valvular factors for symptomatic status. 
Thus, vascular factors supplement a set of indepen-
dent correlates of symptoms development, beyond pure 
AS severity and EF, including subtle LV systolic impair-
ment [15], diastolic dysfunction [16] and elevated LV fill-
ing pressures [17]. Because the risk of mortality rises dra-
matically after the onset of symptoms in AS, exploration 
of mechanisms underlying early changes in LV structure 
appears crucial for better understanding of AS natural 
history. Since LVH frequently develops in an early stage 
of AS and precedes symptoms development, prognostic 
consequences of LVH has long attracted researchers’ at-
tention.
Left ventricular hypertrophy – a predictor 
of adverse outcome in AS
According to traditional teaching, LVH reflects LV ad-
aptation to pressure overload and enables the mainte-
nance of LV systolic performance in AS. However, contrary 
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to expectations, the magnitude of LVH is associated with 
worse, not better, prognosis. In a prospective study, Gerdts 
et al. [18] evaluated LV mass and its prognostic signifi-
cance in 1,656 patients with asymptomatic mild-moder-
ate AS with no evidence of coronary heart disease, heart 
failure, peripheral artery disease, diabetes or renal insuf-
ficiency, participating in the SEAS trial. By following the 
patients for about 4 years, they were able to demonstrate 
that a higher LV mass at baseline was associated with 
various clinical end-point outcomes, i.e. all-cause death, 
cardiovascular (CV) death, ischemic CV events (myocar-
dial infarction, stroke, coronary revascularization and CV 
death) and so-called aortic valve events, i.e. a joint com-
posite outcome of aortic valve replacement, CV death 
or hospitalization for heart failure due to AS [18]. It is 
noteworthy that these associations, when quantified per 
1-SD increase in LV mass, were stronger for LV mass during 
the follow-up (“in-study” LV mass) compared to baseline 
LV mass [18]. Additionally, the negative prognostic effect 
of in-study LV mass, when analyzed as a time-dependent 
covariate, remained significant upon extensive multi-
variate adjustment for AS severity, age, sex, body mass 
index, hypertension, randomized study treatment, EF, LV 
concentricity (i.e. relative LV wall thickness) and valvu-
lo-arterial impedance [18]. Accordingly, the ability of LV 
mass to predict adverse CV events appears to be linked 
to LVH by itself, not to a  combination of LVH and risk 
factors affecting outcome. In particular, during the 4-year 
period, the annual progression rate of AS severity was 
similar in the LVH and non-LVH group, despite LVH prev-
alence nearly doubling [18]. Even though LVH has largely 
been considered a compensatory response to increased 
systolic LV pressures from AS, Gerdts et al. suggested 
that LVH development appears multifactorial with its det-
rimental effects prevailing, especially when LV mass is 
excessive relative to hemodynamic load [18].
The concept of excessive LVH was first suggested by 
Italian researchers who validated a  formula which en-
ables the quantification of inappropriately high LV mass, 
i.e. beyond the value predicted from hemodynamic load, 
gender and height [4, 19]. In their hands, excessive LVH 
was defined as an observed-to-predicted LV mass ratio 
greater than 128%, i.e. the 95th percentile of its distribu-
tion in a reference population of 393 normotensive sub-
jects, and termed “inappropriately high LV mass (iLVM)” 
[4, 19]. The prevalence of iLVM was as high as 37% in 
941 hypertensive patients enrolled in the LIFE study 
[20], whereas the respective proportion averaged 16.6% 
in 1,614 SEAS trial participants with mild or moderate 
AS [21], and 24% in an early report by Mureddu et al. 
[22] of 100 AS subjects. Of note, in the latter study, the 
prevalence of iLVM tended to increase with the degree of 
AS severity, averaging 16%, 26% and 32% in those with 
a mild, moderate or severe grade of valve obstruction, re-
spectively [22]. Like in essential hypertension [20], meta-
bolic risk factors (obesity and metabolic syndrome) were 
also confirmed as “non-hemodynamic” contributors to 
iLVM in AS subjects with mild or moderate AS recruited 
to the SEAS [23] and ASTRONOMER [24] trials. 
Cioffi et al. [21] not only reported the prevalence of 
iLVM in AS, but also described its correlates. According 
to their study, compared to patients with an appropri-
ate LV mass (i.e., between 73% and 128% of the mea-
sured-to-predicted LV mass), subjects with iLVM did 
not differ in age, AS severity or prevalence or severity 
of hypertension. In contrast, those with iLVM were more 
frequently male, with a  considerably higher relative LV 
wall thickness (by 35%). Of note, iLVM was associated 
with decreased circumferential end-systolic LV wall stress 
(by 10%), slightly lower EF (by 4%) but pronounced (by 
30%) reductions of stress-corrected LV midwall fractional 
shortening [21], a parameter better than EF as an index 
of LV systolic performance in concentric LV geometry [25]. 
Importantly, as many as 88% of patients with iLVM had 
depressed stress-corrected midwall fractional shorten-
ing, compared to only 15% in those with an appropriate 
LV mass [21]. 
Based on these findings, Cioffi et al. [21] concluded 
that iLVM in asymptomatic AS was probably a  sign of 
concomitant load-independent primary myocardial dys-
function which could underlie excessive LVH as an in-
effective compensatory mechanism whose goal would 
be to restore LV performance via reduced systolic LV 
wall stress in accordance with the Laplace law. That LV 
end-diastolic internal diameter, a  raw index of preload, 
was only slightly lower (by 3%) in the presence of iLVM is 
also in agreement with this hypothesis [21]. The notion 
of depressed LV contractility offers a plausible explana-
tion for the association of iLVM and impaired LV midwall 
systolic function with a surprisingly lower, not higher, LV 
afterload [21], consistent with analogous observations in 
hypertensive patients [5, 26].
Development of excessive LVH appears not only a cor-
relate of intrinsic LV systolic dysfunction [3–5, 21], but is 
also associated with impaired coronary flow reserve [6] 
and LV diastolic dysfunction [3], a substrate of heart fail-
ure with preserved EF [8], the predominant form of heart 
failure in the elderly. These abnormalities may be respon-
sible for the independent ability of iLVM, but not LVH or 
LV mass index, to predict adverse CV outcome in 209 pa-
tients with asymptomatic severe AS free from coexistent 
diseases (except for hypertension and diabetes) followed 
for almost 2 years [27]. Although iLVM was associated 
with depressed stress-corrected LV midwall fractional 
shortening, only iLVM entered the final regression model 
as an independent prognosticator [27]. The results were 
similar after exclusion of aortic valve replacement from 
the composite end-point outcome encompassing also 
all-cause death and hospital admissions for myocardial 
infarction or heart failure. That patients with iLVM had 
a 4.5-higher risk of any of these adverse CV events than 
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their counterparts with appropriate LVH [27] strongly 
supports the clinical relevance of excessive LVH in AS.
Prognostic implications of the presence 
or absence of pre-operative LVH in AS 
patients undergoing surgical aortic valve 
replacement
Early reports clearly defined associations between 
pre-operative LVH and mortality after surgical aortic valve 
replacement. In a group of 60 AS subjects, Orsinelli et al. 
[28] identified higher relative LV wall thickness, an index 
of LV concentricity, as a  risk factor for early in-hospital 
mortality following surgery. In a large survey of 5,083 pa-
tients operated on for AS, Duncan et al. [29] described 
greater LV concentricity, not LVH by itself, as an indepen-
dent predictor of in-hospital mortality. That concentric LV 
geometry may pose a risk for late post-operative progno-
sis was also suggested by Debry et al. [30], who reported 
that only LV concentric remodeling (i.e. elevated relative 
LV wall thickness in the absence of LVH) independent-
ly predicted mortality over a  mean follow-up of about 
3 years when surgical management was considered, in 
331 asymptomatic or mildly symptomatic patients with 
AS and preserved EF. With regard to AS subjects under 
conservative management, the highest risk of 3–4-year 
mortality was found for concentric remodeling followed 
by concentric LVH [30].
Intriguingly, not only the magnitude of LVH predicts ad-
verse early and late post-operative outcome, but also the 
lack of LVH, a putative compensatory mechanism, is not 
associated with worse prognosis. As early as over 20 years 
ago, Seiler and Jenni [31] observed an absence of LVH ac-
cording to LV mass criteria in 21 out of 189 study subjects 
with severe AS and no coronary artery disease. Those LVH-
free AS patients exhibited either concentric LV remodeling 
(57%) or normal LV geometry (43%) [31]. Counterintuitive-
ly, ergometric working capacity was higher in the absence 
of LVH. Importantly, 5–6-month survival after aortic valve 
replacement was not significantly worse in patients with-
out LVH, but post-operative deaths occurred exclusively in 
patients with elevated relative LV wall thickness irrespec-
tive of LVH [31]. Similar findings were reported 18 years 
later by Barasch et al. [32], who observed no LVH in 36% of 
512 subjects with severe symptomatic AS and a preserved 
EF. In that study, rates of aortic valve replacement were 
similar regardless of the presence of LVH, and 3.5-year 
mortality tended to be even lower among patients with-
out LVH [32]. Additionally, a significantly improved survival 
was found only in subjects with neither LVH nor concentric 
remodeling [32]. Accordingly, these studies further support 
the previously mentioned negative prognostic effect of LV 
concentricity [28–30]. Barasch et al. [32] speculated that 
as yet unidentified mechanisms are likely to offset the po-
tential detrimental effect of excessive LV afterload in AS 
patients free of LVH and with a normal LV geometry. 
The above unexpected findings in AS subjects with-
out LVH may reflect pathophysiological mechanisms 
which are not limited to AS, being operational also in 
hypertension, the most prevalent cause of LV pressure 
overload. Indeed, patients with inadequate LV mass, i.e. 
the measured LV mass below the 10th [27] or the 2.5th 
percentile [33] of the distribution of the LV mass predict-
ed from the individual hemodynamic load in the refer-
ence population [4, 19], had a similar rate of adverse CV 
events to those with appropriate LV mass in 209 patients 
with asymptomatic severe AS [27] and 294 hypertensive 
subjects [33]. Intriguingly, in the latter study, inadequate 
LV mass was associated with supranormal afterload-cor-
rected midwall and endocardial systolic function, which, 
jointly with excessive afterload, elevated cardiac index 
and marginally higher heart rate, was suggestive of sym-
pathetic activation [33]. 
Detailed pathways underlying the protective role of 
absent LVH despite afterload excess and possible sym-
pathetic predominance remain to be elucidated and may 
also be applicable to patients with AS.
Relevance of gender for LV remodeling  
in AS
Sex-dependent differences in LV remodeling were 
reported in patients with AS. Compared to men, wom-
en with severe isolated AS exhibit a smaller LV size with 
greater LV concentricity and higher endocardial fractional 
shortening and EF [34]. These differences were linked to 
enhanced expression of profibrotic genes and myocardial 
fibrosis in men, presenting frequently with more eccen-
tric LVH associated with LV dilation [35]. It was also sug-
gested that a lower magnitude of LV fibrosis could also 
be responsible for faster regression of LVF after aortic 
valve replacement in females [36].
On the basis of their previous findings [36], in an ele-
gant study Petrov et al. [37] calculated the so-called LVH 
index, a single parameter which integrates LV concentric-
ity and LVH appropriateness relative to LV afterload. More 
negative values of the LVH index correspond to more ap-
propriate afterload-corrected LV mass and concentric LV 
geometry, i.e. adaptive LVH, while positive values reflect 
maladaptive LV remodeling with a  larger LV cavity and 
excessively high LV mass disproportionate to LV afterload 
[37]. The authors demonstrated a  higher proportion of 
maladaptive LV remodeling (i.e. a positive LVH index) in 
men versus women, especially about 3–4 years after aor-
tic valve replacement for severe AS (51% vs. 25%), but 
also pre-operatively (55% vs. 38% for males and females, 
respectively) [37]. Moreover, maladaptive LV remodeling 
at surgery was associated with worse 3-year survival 
exclusively in women. Recently, the presence of residual 
LVH after aortic valve surgery was linked to 6-year inci-
dence of non-fatal CV hospitalizations especially in wom-
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en [38], which further supports the long-term prognostic 
significance of gender after aortic valve implantation.
Left ventricular hypertrophy regression 
following surgical aortic valve replacement 
– prognostic implications
Aortic valve replacement decreases LV afterload, 
counteracting the main stimulus for LVH in AS. However, 
although LVH regression is a well-recognized phenome-
non following surgery, clinical consequences of post-op-
erative LV mass lowering are far from being unequivocal-
ly established. Obviously, although LVH regression occurs 
rather uniformly irrespective of valve type, predominant-
ly during the first 3–6 months after surgery, EF improve-
ment is evident only in patients with pre-operative LV 
dysfunction [39]. Several pivotal studies identified the 
time course, determinants and prognostic consequences 
of LVH regression after surgical aortic valve replacement 
for severe AS. Ali et al. [40] demonstrated that only LV 
mass reduction of more than 150 g at 1 year after sur-
gery was an independent, albeit rather weak, predictor 
of improved 10-year actuarial survival. Later studies of 
Beach et al. [41] and Hatani et al. [42] demonstrated 
a regression of LVH during the first months after surgery, 
whereas LV mass remained relatively constant after 1–2 
years. This is in agreement with a report of a large series 
of AS subjects with pre-operative LVH, described by Une 
et al. [43], who experienced maximal LV mass regression 
at a mean of 25 months.
In contrast, left atrial (LA) diameter decreased rap-
idly during the first month in selected individuals and 
then reached a plateau [42], suggesting the contribution 
of acute LV unloading to the normalization of LA vol-
ume. Beach et al. [41] observed associations of residual 
post-operative LVH at 2 years with – in decreasing level 
of importance – pre-operative LVH, larger pre-procedural 
LA diameter, and worse LV systolic function. Hatani et al. 
[42] reported independent relations between post-oper-
ative LVH at 1 year and pre-operative LVH and LA dila-
tation, while pre-procedural LA dilatation was the stron-
gest correlate of post-procedural LA enlargement in both 
studies [41, 42]. Although residual LVH at 2 years was 
a univariate predictor of late all-cause mortality at 5–10 
years, as reported by Beach et al. [41], severe pre-oper-
ative LVH (≥ 180 g/m2) was a more significant prognos-
ticator, albeit weaker than severe LA dilatation (≥ 5 cm), 
because post-operative and pre-operative LV mass were 
strongly interrelated. They concluded that marked LVH 
and LA dilatation corresponded to reduced long-term 
survival in even asymptomatic AS patients and early sur-
gical intervention could possibly be beneficial in these 
subjects [41]. In partial accordance with these findings, 
Hatani et al. [42] observed a higher 3-year risk of either 
total mortality or adverse CV events in those with both 
residual post-operative LVH (according to the classical 
criteria) and persistent LA enlargement (≥ 40 ml/m2) at 
1 year after successful aortic valve replacement, com-
pared to the remainder. 
Thus, independent contributions of LVH and LA size, 
a  marker of increased LV filling pressure, to long-term 
prognosis after aortic valve replacement indicate the rel-
evance of both pre-procedural LV diastolic dysfunction 
and its substrate, i.e. LVH, especially in AS subjects with 
persistent LVH at 1–2 years after surgery.
Left ventricular hypertrophy regression 
following transcatheter aortic valve 
implantation – prognostic implications
Like after aortic valve surgery, LVH regression takes 
place also after TAVI. However, there are considerable 
differences in LV remodeling after TAVI compared to sur-
gical aortic valve replacement. The large data set of the 
PARTNER trial allowed the time course of LV mass chang-
es and its determinants in patients referred for TAVI to 
be studied in detail. In addition, comparisons could be 
made between subjects undergoing TAVI and surgical 
aortic valve replacement [44]. 
In a  longitudinal echocardiographic study of high-
risk patients enrolled in the PARTNER I  trial (cohort A), 
LV mass index regression was slower in TAVI patients 
versus those randomized to surgery (TAVI vs. surgery: 
0.7% vs. 6.7% at 1 months), but the magnitude of LVH re-
gression at 1–2 years was similar (TAVI vs. surgery: 9.4% 
vs. 13.3% at 1 year; 17.3% vs. 21.9% at 2 years) [45]. It 
was proposed that this effect could be linked to higher 
occurrence of aortic regurgitation caused by post-TAVI 
paravalvular leak (PVL), whose degree diminished over 
time (TAVI vs. surgery: 12.2% vs. 0.9% at 1 month and 
6.8% vs. 1.9% at 1 year for moderate to severe PVL) [44]. 
So, post-TAVI PVL could first delay LVH regression, which 
might later catch up with LV remodeling recovery in the 
surgical cohort owing to a gradual decrease of PVL mag-
nitude [45, 46]. 
It is noteworthy that improvements in EF were in-
dependent of LVH regression in the PARTNER cohort A. 
Despite delayed LVH regression in TAVI patients, EF in-
creased already at discharge (by about 6%), whereas af-
ter surgery a similar change in EF was found not earlier 
than at 1 month, yet with similar improvements in EF (by 
8% vs. baseline) in both groups at 1–2 years [45]. Impor-
tantly, post-TAVI rises in EF (by 6% and 7% at 1 month 
and 1 year, respectively) preceded LVH regression also in 
inoperable extreme-risk patients from the PARTNER co-
hort B, in whom the LV mass index fell by 14% at 1 year 
(similar to cohort A), but by less than 3% at 1 month [47].
In contrast to PVL, the prevalence of prosthesis-patient 
mismatch (PPM), diagnosed when the effective orifice 
area is too small for the patient’s body size (≤ 0.85 cm2/ 
m2; < 0.65 cm2/m2 for severe PPM) was higher in surgi-
cally managed AS patients (surgery vs. TAVI: 60.0% vs. 
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43.8–46.4%, or 28.1% vs. 13.6–19.7%) [48]. In multivar-
iate analysis, any PPM was associated with less LVH re-
gression at 1 year in the surgical arm of the PARTNER 
cohort A and the TAVI nonrandomized continued access 
registry cohort [48]. Severe PPM independently predicted 
higher 2-year mortality in the randomized surgical cohort 
and 1-year mortality in the TAVI registry cohort without 
post-procedural aortic regurgitation [48].
Among patients with severe LVH (≥ 149 g/m2 in men; 
≥ 122 g/m2 in women) included in the PARTNER cohort 
A and the nonrandomized registry who survived 1 year 
after TAVI, 2 patterns of LVH regression were identified 
[49]. In about one-half of the subjects, an early decline 
of LV mass occurred at 1 month, with no further chang-
es during the remainder of the year. As this was paral-
leled by a drop in relative LV wall thickness on the 30-day 
echocardiogram, LVH regression resulted primarily from 
rapid decreases in LV wall thickness, not altered LV di-
mensions. In the remainder, LV mass decreased gradu-
ally between 1 month and 1 year, although final 1-year 
relative LV mass reductions were lower (12%) than in 
those with greater LV mass regression at 1 month (23%) 
[49]. Early LVH regression was independently predicted 
by female gender, absence of a pacemaker at baseline, 
greater pre-procedural LV midwall shortening and lower 
mean transvalvular pressure gradient at 1 month after 
TAVI, not PPM or aortic regurgitation [49]. Notably, the 
pattern of rapid regression of severe LVH was associated 
with a  2-fold lower rate of hospitalizations, mainly for 
heart failure, at 1-year follow-up, and a trend toward bet-
ter quality of life [49]. 
The relationship between female sex and earlier/
greater post-TAVI LVH regression [49] could have contrib-
uted, in addition to higher baseline comorbidity among 
men [44, 50], to a lower (by about one-third) risk of all-
cause 2-year mortality in women, randomized to TAVI, 
especially by a transfemoral approach, from the PARTNER 
cohort A [51].
Beneficial effects of LV mass regression could also 
be responsible for an association of pre-operative con-
centric LV remodeling with higher all-cause mortality at 
1 year after TAVI, as recently reported by Rymuza et al. 
[52]. Indeed, LV mass tended to increase after TAVI only 
in those with concentric remodeling, in contrast to oppo-
site trends in those with concentric or eccentric LVH [52]. 
Transcatheter aortic valve implantation- 
-specific effects on LV function recovery
A  variety of mechanisms have been proposed as 
a basis for clinical benefits of LVH regression after TAVI. 
Although Tzikas et al. [53] did not observe any improve-
ment of LV function despite post-TAVI LVH regression 
1 year after TAVI, later reports suggested better LV 
function in post-TAVI subjects vs. surgery. First, as pre-
viously mentioned, TAVI was associated with earlier EF 
improvements than surgery, preceding LVH regression 
[45]. Second, in a tissue tracking cardiac magnetic res-
onance study, Nucifora et al. [54] observed correlations 
between the degree of LV mass regression and improve-
ment in global LV strain in 3 directions (longitudinal, ra-
dial and circumferential) at about 15 months after both 
TAVI and surgical aortic valve implantation. Moreover, 
an early post-procedural increase in global LV longitu-
dinal strain was found only after TAVI, in contrast to 
a  transient decrease in that parameter after surgery, 
despite no changes of EF [46]. Thus, compared to sur-
gery, TAVI might be associated with an additional early 
benefit for LV systolic function, regardless of that ac-
companying late LVH regression. Third, Costantino et al. 
[55] reported greater decreases in LV mass, relative wall 
thickness and the E/E′ ratio, a noninvasive estimate of 
LV filling pressure in post-TAVI versus surgical patients 
at 2 months after the procedure. Furthermore, 2-month 
RWT reductions and simultaneous lowering of the E/E′ 
ratio were interrelated exclusively after TAVI, not after 
surgery, regardless of post-procedural falls in valvu-
lo-arterial impedance [55]. 
Renin-angiotensin system blockade in AS 
– a tool to inhibit LVH development and 
potentiate post-procedural LVH regression?
Clinical benefits observed in patients with post-oper-
ative or post-TAVI regression of LVH suggest that drugs 
with the highest ability to attenuate LVH in arterial hy-
pertension, i.e. renin-angiotensin system (RAS) blockers 
[2], would be indicated also for this purpose in AS. In 
fact, angiotensin-converting enzyme blockers (ACEI) and 
angiotensin receptor blockers (ARB) exert an additional 
protective effect against LVH, beyond that resulting from 
blood pressure lowering [2, 56]. RAS blockade attenuates 
both cardiomyocyte hypertrophy and the expansion of 
extracellular matrix [2, 56], and myocardial fibrosis with 
overexpression of the angiotensin-converting enzyme ac-
companies severe AS [57]. Weidemann et al. [58] demon-
strated that a greater extent of pre-operative myocardial 
fibrosis was associated with longitudinal LV systolic dys-
function and no clinical improvement after surgery for 
severe symptomatic AS. On the other hand, according to 
traditional views, severe AS is perceived as a relative, yet 
recognized, contraindication to ACEI and ARB, owing to 
the risk of hypotension and coronary hypoperfusion. 
Nevertheless, a  report from a  large Scottish registry 
of a total of 2,117 patients with AS suggested good tol-
erance of ACEI or ARB (i.e. no effect on blood pressure), 
associated with even a lower risk of all-cause mortality 
and adverse CV events within an about 4-year follow-up, 
regardless of stenosis severity [59]. It can be speculated 
that this effect might partially be linked to lower LV mass 
in patients on ACEI or ARB. In agreement with this con-
cept, in a  cross-sectional analysis of 428 subjects with 
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severe AS and preserved EF, Goh et al. [60] observed de-
creased odds of having LVH in those treated with ACEI 
or ARB with reference to their counterparts receiving 
neither ACEI nor ARB. The notion of potential benefits of 
RAS blockade in AS is also consistent with a prospective 
study by Bang et al. [61], who observed a lower time-de-
pendent increase in LV mass, but no effect on AS progres-
sion rate, in 769 ACEI or ARB users over a mean follow-up 
of 4.3 years of 1,873 patients with mild or moderate AS 
participating in the SEAS trial. In addition, the incidence 
of all study end-points, including all-cause death, CV 
death or sudden cardiac death was similar according to 
the use of RAS antagonists [61]. Finally, potential clinical 
benefits of ACEI/ARB in less than severe AS could also be 
linked to their capability to slow down the progression 
of renal function decline, recently shown to contribute 
to the development of excessive LVH in moderate AS, as 
described by our group [62].
Anyway, safety concerns regarding RAS blockade in 
severe AS are not more valid after a successful TAVI or 
surgical aortic valve replacement. Thus, RAS blockade ap-
pears to be a  promising tool to further potentiate LVH 
regression after TAVI or aortic valve surgery. Furthermore, 
the capability of ACEI/ARB to attenuate also myocardial 
fibrosis [56], presumably less responsive to post-proce-
dural afterload reduction than myofibrillar hypertrophy, 
is especially promising in post-TAVI patients, because the 
extent of preoperative-myocardial fibrosis predisposed 
to the post-operative persistence of residual LVH [38]. 
In a  registry of 1,215 patients undergoing TAVI, Ochiai 
et al. [63] recently demonstrated 4-fold higher 6-month 
regression of LV mass (9% vs. 2%) and over 2-fold lower 
all-cause 2-year mortality in patients treated with ACEI or 
ARB after the procedure. 
Hence, further studies are warranted to optimize 
pre-interventional and post-interventional strategies 
aimed at counteracting LV remodeling in AS.
Summary
Left ventricular hypertrophy has traditionally been 
perceived as a compensatory mechanism aimed at the 
maintenance of LV systolic function under chronic LV 
pressure overload, such as arterial hypertension and 
AS. Left ventricular hypertrophy development is depen-
dent on afterload-modifying factors, i.e. AS severity and 
reduced compliance of large systemic arteries, with an 
additional impact of non-hemodynamic contributors, e.g. 
metabolic syndrome and chronic kidney disease. Nota-
bly, in AS patients, both the presence and magnitude of 
LVH are associated with an increased risk of adverse CV 
events, especially when LV mass is inappropriately high, 
i.e. disproportionate to LV afterload. Importantly, the neg-
ative prognostic effect of excessive LVH or LV concentric-
ity in severe AS was observed irrespective of treatment 
strategy (medical therapy or interventional approach), 
being also reported in patients after surgical valve re-
placement or TAVI, in whom severe pre-operative LVH 
and its post-operative persistence lessened the clinical 
Figure 1. Detrimental effects of excessive left ventricular (LV) hypertrophy, i.e. inappropriately high LV mass 
disproportionate to LV afterload, in aortic stenosis
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benefits of aortic valve-related interventions. In particu-
lar, early LVH regression after TAVI was associated with 
better LV function recovery and reduced risk of heart 
failure hospitalizations at 1-year follow-up. Intriguingly, 
patients with severe AS and inadequate LV mass (i.e. too 
low) had a similar CV risk to those with an appropriate LV 
mass relative to LV afterload, despite markedly increased 
LV wall stress. Thus, theoretical benefits of afterload 
reduction are presumably offset by detrimental con-
sequences of LVH (Figure 1), including LV diastolic dys-
function, impairment of coronary flow reserve and pro-
pensity to ventricular arrhythmias. In addition, subtle LV 
systolic dysfunction at the midwall level and reduced LV 
wall stress were described in subjects with AS and inap-
propriately high LV mass. Accordingly, excessive LVH can 
also be enhanced by primary myocardial dysfunction, 
being thereby a  likely compensatory, albeit inefficient 
mechanism whose goal would be to restore LV function 
via reduced LV wall stress. Irrespective of pathophysio-
logical considerations, drugs with the highest ability to 
attenuate LVH, ACEI and ARB seem a promising tool in 
AS, especially after a successful aortic valve replacement, 
when classical safety concerns regarding RAS blockade in 
severe AS are no longer present. 
Conclusions
Excessive LVH appears to be a  potential additional 
therapeutic target in AS. Randomized studies are war-
ranted with regard to RAS blockade in AS patients with 
severe LVH, especially after surgical or transcatheter aor-
tic valve replacement, in order to further optimize long-
term prognosis. 
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